Appeals court strikes potentially dire blow to ObamaCare

A federal appeals court on Tuesday dealt a major blow to ObamaCare, ruling that tax subsidies crucial to the law's functionality may be null in more than half the states.
The 2-1 decision, which could have drastic ramifications for the health care law, rests entirely on a snippet of poorly-worded language in the original bill. The law gave states a choice between setting up their own health care exchanges where residents could buy insurance, or having the federal government run exchanges for them. But the law guaranteed subsidies for buying coverage only "through an Exchange established by the State." Given that, the court ruled that the feds can't subsidize coverage for people who purchase insurance through federally-run exchanges.
Thirty-four states, most of them dominated by GOP governors or legislatures, declined to set up their own exchanges.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"We reach this conclusion, frankly, with reluctance," the D.C. Circuit Court of Appeals wrote. "At least until states that wish to can set up Exchanges, our ruling will likely have significant consequences both for the millions of individuals receiving tax credits through federal Exchanges and for health insurance markets more broadly. But, high as those stakes are, the principle of legislative supremacy that guides us is higher still."
The subsidies are intended to make insurance affordable to millions of low-income Americans; nixing the subsidies could affect more than 7.3 million people, according to one recent analysis. The law's success relies on broadening the pool of insured adults to spread costs and risks, so anything that rolls back enrollments — as the ruling very well could do — could undermine the law entirely.
The federal government can appeal the ruling to the full D.C. Circuit Court.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Jon Terbush is an associate editor at TheWeek.com covering politics, sports, and other things he finds interesting. He has previously written for Talking Points Memo, Raw Story, and Business Insider.
-
Today's political cartoons - February 22, 2025
Cartoons Saturday's cartoons - bricking it, I can buy myself flowers, and more
By The Week US Published
-
5 exclusive cartoons about Trump and Putin negotiating peace
Cartoons Artists take on alternative timelines, missing participants, and more
By The Week US Published
-
The AI arms race
Talking Point The fixation on AI-powered economic growth risks drowning out concerns around the technology which have yet to be resolved
By The Week UK Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published